Log In
person
Gelesis Holdings Inc
GLSHQ
summarize
2 total product lines
calendar_month
Revenue as of 12/31/2022
| Reporting Segmentarrow_drop_up | Product Line | Amount (USD) | Percentage |
|---|---|---|---|
| keyboard_arrow_right | Reporting Segment & Product Line | Amount (USD) | Percentage |
| Pharma for Obesity |
Branded Pharmaceuticals; sold through self-paid telehealth
These companies research, develop, and manufacture patented drugs that are sold through telehealth channels and paid for by the patient, without health insurance.
|
25.56M | 99.19% |
| Pharma for Obesity |
Pharmaceutical Patent Licensing
These companies collect royalties from pharma and biotech companies who make biotech products they developed or products that incorporate their technologies.
|
0.21M | 0.81% |
| keyboard_arrow_down |
Pharma for Obesity
Branded Pharmaceuticals; sold through self-paid telehealth
|
25.56M | 99.19% |
| keyboard_arrow_right |
These companies research, develop, and manufacture patented drugs that are sold through telehealth channels and paid for by the patient, without health insurance.
|
||
| keyboard_arrow_down |
Pharma for Obesity
Pharmaceutical Patent Licensing
|
0.21M | 0.81% |
| keyboard_arrow_right |
These companies collect royalties from pharma and biotech companies who make biotech products they developed or products that incorporate their technologies.
|
||